NASDAQ:BMRN
BioMarin Pharmaceutical Inc. Stock News
$75.52
-0.380 (-0.501%)
At Close: May 24, 2024
BioMarin hit with FDA request for additional data to resolve hold on gene therapy trial
10:20pm, Thursday, 17'th Feb 2022 Seeking Alpha
The FDA is requesting BioMarin Pharmaceutical (BMRN) provide additional data to lift a clinical hold on a phase 1/2 study of candidate BMN 307 issued in September 2021.
Avoro Capital Advisors LLC Buys Apellis Pharmaceuticals Inc, SPDR Biotech ETF, Biomarin ...
06:38pm, Tuesday, 15'th Feb 2022 GuruFocus
Related Stocks: APLS , BMRN , SRPT , XENE , ALNY , SNDX , XBI , KRYS , IOBT , XLRN , VRTX , TRIL , DCPH , BIIB , MRUS ,
BioMarin Sells Priority Review Voucher For $110M
03:34pm, Wednesday, 09'th Feb 2022 Benzinga
BioMarin Pharmaceutical Inc (NASDAQ: BMRN ) has agreed to sell the Rare Pediatric Disease Priority Review Voucher (PRV) for $110 million to an undisclosed purchaser . The Company received the voucher … Full story available on Benzinga.com
BioMarin Sells Priority Review Voucher for $110 Million
01:31pm, Wednesday, 09'th Feb 2022 Investors BiomarinBioMarin Sells Priority Review Voucher For $110M
10:34am, Wednesday, 09'th Feb 2022
BioMarin Pharmaceutical Inc BMRN has agreed to sell the Rare Pediatric Disease Priority Review Voucher (PRV) for $110 million to an undisclosed purchaser. Get the Inside Access Traders Are Using to
Despite recent gains, these three biotechs still have upside potential in 2022 - Credit Suisse
08:47pm, Monday, 07'th Feb 2022 Seeking Alpha
Credit Suisse argues that BioMarin Pharmaceutical <>, United Therapeutics <>, and Insmed Incorporated <> still carry further upside opportunities in 2022, despite…
12 biotech stocks to consider buying now as prospects for the sector brighten this year
02:01pm, Monday, 07'th Feb 2022 MarketWatch
Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double.
Did Hedge Funds Catch A Break With BioMarin Pharmaceutical Inc. (BMRN)?
08:27pm, Sunday, 06'th Feb 2022 Insider Monkey
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
12 biotech stocks to consider buying now as prospects for the sector brighten this year
04:53pm, Sunday, 06'th Feb 2022
Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double
BioMarin reports positive data from phase 3 trial of gene therapy in hemophilia A
05:43pm, Friday, 04'th Feb 2022 Seeking Alpha
BioMarin Pharmaceutical <> reported sustained bleed control in certain patients with severe hemophilia A in a two-year analysis of a phase 3 study evaluating
BofA: We like Pfizer and BioMarin going into earnings
05:47pm, Friday, 28'th Jan 2022 Yahoo Finance
Bank of America Global Research released their stock ratings and price targets for 15 biopharmaceutical companies as part of their recent report titled 4Q21 Biopharma Preview - What We Think Will Matter. Of these 15, BofA cited Pfizer and BioMarin as being positioned particularly strongly as earnings season starts to kick off.
LABU - A Compelling Biotech Trade
04:24pm, Wednesday, 26'th Jan 2022
LABU - A Compelling Biotech Trade
BioMarin Pharmaceutical (BMRN) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference
04:41pm, Monday, 24'th Jan 2022 Seeking AlphaBioMarin CEO: There are biotech companies 'that probably should not be on the market today'
12:00am, Sunday, 16'th Jan 2022
BioMarin CEO JJ Bienaimé joins Yahoo Finance Live's Julie Hyman and Anjalee Khemlani to discuss the company's first gene therapy product targeted to patients dealing with hemophilia, the future of bi
BioMarin CEO says study results for hemophilia gene therapy are as 'good as we could hope'
07:36pm, Tuesday, 11'th Jan 2022
Jean-Jacques Bienaime, CEO and chairman of BioMarin Pharmaceutical, appeared on Tuesday's episode of "Mad Money," discussing trial results for the company's hemophilia gene therapy.
